Previous 10 | Next 10 |
home / stock / aspcf / aspcf news
Acerus Pharmaceuticals Corporation (“Acerus” or the “Company”) (TSX:ASP, OTCQB:ASPCF) today announced the acceptance of two NATESTO ® clinical studies for presentation at the American Urological Association’s AUA2020 Scientific Program. The AUA2020 mee...
Acerus Pharmaceuticals Corporation (“Acerus” or the “Company”) (TSX:ASP, OTCQB:ASPCF) today announced the acceptance of a scientific abstract reporting the results of the NATESTO ® Spermatogenesis Study by the Endocrine Society for presentation at their Annua...
Acerus Pharmaceuticals Corporation (“Acerus” or the “Company”) (TSX:ASP, OTCQB:ASPCF) today announced that the dossier filed as a Decentralized Procedure in 19 European countries for the approval of NATESTO ® has been withdrawn. The regulatory dossier was fil...
Acerus Pharmaceuticals Corporation (“Acerus” or the “Company”) (TSX:ASP, OTCQB:ASPCF) today announced that it has closed the previously announced amendment and restatement of the US$5.0 million subordinated secured term loan facility previously entered into on July...
Acerus Pharmaceuticals Corporation (“Acerus” or the “Company”) (TSX:ASP, OTCQB:ASPCF) today announced that it entered into an amendment agreement related to its existing credit facility with SWK Funding LLC (“SWK”) and that it received a waiver letter...
Acerus Pharmaceuticals Corporation (TSX:ASP; OTCQB: ASPCF) announced today that Edward Gudaitis, President and Chief Executive Officer, will present an overview of the company at the 12 th Annual LD Micro Main Event investor conference at 3:40 pm Pacific Time on Tuesday December 10, 2019 at ...
Closing conditions waived - Amended & Restated Partnership Agreement is now closed Acerus-Aytu jointly led commercial effort behind NATESTO ® in the United States is now initiated Acerus Pharmaceuticals Corporation (TSX:ASP, OTCQB:ASPCF) today announced that the rev...
Acerus Pharmaceuticals Corporation (ASPCF) Q3 2019 Earnings Conference Call November 14, 2019 8:30 AM ET Company Participants Bob Motz – Chief Financial Officer Ed Gudaitis – President and Chief Executive Officer Conference Call Participants Presentation Op...
Acerus Pharmaceuticals ( OTCQB:ASPCF ): Q3 GAAP EPS of -$0.02. More news on: Acerus Pharmaceuticals Corporation, Earnings news and commentary, Healthcare stocks news, , Read more ...
Acerus Pharmaceuticals Corporation (“Acerus” or the “Company”) (TSX:ASP; OTCQB:ASPCF) today reported its financial results for the three- and nine-month period ended September 30, 2019. Unless otherwise noted, all amounts are in US dollars and are prepared in accor...
News, Short Squeeze, Breakout and More Instantly...
Acerus Pharmaceuticals Corp Company Name:
ASPCF Stock Symbol:
OTCMKTS Market:
Acerus Pharmaceuticals Corp Website:
TORONTO, May 25, 2023 (GLOBE NEWSWIRE) -- As announced on January 26, 2023, Acerus Pharmaceuticals Corporation (the “ Company ” or “ Acerus ”) and its subsidiaries were granted creditor protection pursuant to an order (the “ Initial Order ”) g...
TORONTO, March 14, 2023 (GLOBE NEWSWIRE) -- On January 26, 2023, Acerus Pharmaceuticals Corporation and certain of its subsidiaries (collectively, “ Acerus ”) were granted protection pursuant to an order (the “ Initial Order ”) issued under the Companies ...
TORONTO, Jan. 26, 2023 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (the “ Company ” or “ Acerus ”) (TSX: ASP; OTCQB: ASPCF) today announced that the Company and its subsidiaries, Acerus Biopharma Inc., Acerus Labs Inc. and Acerus Pharmaceuticals USA,...